Centessa Pharmaceuticals PLC (CNTA) — SEC Filings

Overview

Centessa Pharmaceuticals PLC (CNTA) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DFAN14A filed on Mar 31, 2026: Centessa Pharmaceuticals plc filed a DFAN14A on March 31, 2026, related to additional definitive proxy soliciting materials. The filing includes documents such as the DFAN14A form itself and associated graphics. The company's mailing and business addresses are located in Altrincham, Cheshire, UK.

Sentiment Summary

Across 37 filings, the sentiment breakdown is: 2 bearish, 35 neutral. The dominant filing sentiment for Centessa Pharmaceuticals PLC is neutral.

Filing Type Overview

Centessa Pharmaceuticals PLC (CNTA) has filed 1 4, 1 DFAN14A, 18 8-K, 6 10-Q, 2 DEFA14A, 2 DEF 14A, 2 10-Q/A, 4 SC 13G/A, 1 10-K with the SEC between Jan 2024 to Mar 2026.

Filings by Year

2026 · 2025 · 2024

Recent Filings (37)

• Centessa Pharmaceuticals Files Proxy Materials — DFAN14A · Mar 31, 2026 Risk: low
  Centessa Pharmaceuticals plc filed a DFAN14A on March 31, 2026, related to additional definitive proxy soliciting materials. The filing includes documents such
• 4 Filing — 4 · Mar 27, 2026
• Centessa Pharmaceuticals Reports Director/Officer Changes — 8-K · Dec 11, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on December 11, 2025, reporting events as of December 5, 2025. The filing covers the departure of directors or certain
• Centessa Pharmaceuticals Files 8-K — 8-K · Nov 24, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on November 24, 2025, reporting other events and financial statements. The filing does not contain specific financial
• Centessa Pharmaceuticals Enters Material Definitive Agreement — 8-K · Nov 13, 2025 Risk: medium
  Centessa Pharmaceuticals plc entered into a material definitive agreement on November 11, 2025. The company also reported other events and filed financial state
• Centessa's Q3 Loss Widens Amid R&D Surge, Cash Drains — 10-Q · Nov 5, 2025 Risk: high
  Centessa Pharmaceuticals plc reported a net loss of $54.89 million for the three months ended September 30, 2025, an increase from a net loss of $42.57 million
• Centessa's Q2 Loss Widens Amid Soaring R&D Costs — 10-Q · Aug 12, 2025 Risk: high
  Centessa Pharmaceuticals plc reported a net loss of $50.343 million for the three months ended June 30, 2025, an increase from the $43.816 million net loss in t
• Centessa Pharmaceuticals Files 8-K on Shareholder Vote Matters — 8-K · Jun 20, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on June 20, 2025, to report on matters submitted to a vote of its security holders. The filing details the company's c
• Centessa Pharmaceuticals Files 8-K — 8-K · Jun 17, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on June 17, 2025, reporting other events and financial statements as of June 16, 2025. The filing details the company'
• Centessa Pharmaceuticals Announces Board and Officer Changes — 8-K · May 29, 2025 Risk: low
  Centessa Pharmaceuticals plc announced on May 27, 2025, changes in its board of directors and executive officers. The company also reported on compensatory arra
• Centessa Pharmaceuticals Files DEFA14A Proxy Materials — DEFA14A · May 28, 2025 Risk: low
  Centessa Pharmaceuticals plc filed a Definitive Additional Materials (DEFA14A) on May 28, 2025. This filing relates to their proxy statement and indicates no fe
• Centessa Pharmaceuticals Q1 2025 10-Q Filing — 10-Q · May 14, 2025 Risk: medium
  Centessa Pharmaceuticals plc filed its 10-Q for the period ending March 31, 2025. The filing details financial performance and operational updates for the first
• Centessa Pharmaceuticals Files 2025 Proxy Statement — DEF 14A · May 6, 2025 Risk: low
  Centessa Pharmaceuticals plc filed its definitive proxy statement on May 6, 2025, for its annual meeting of shareholders. The filing outlines the company's gove
• Centessa Pharmaceuticals Files 8-K on Financials — 8-K · Mar 24, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on March 24, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Centessa Pharmaceuticals Enters Material Definitive Agreement — 8-K · Feb 21, 2025 Risk: medium
  Centessa Pharmaceuticals plc entered into a material definitive agreement on February 14, 2025. The filing does not disclose the specific nature or counterparty
• Centessa Pharmaceuticals Files 10-Q/A for Q3 2024 — 10-Q/A · Feb 14, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an amendment (10-Q/A) on February 14, 2025, for the quarterly period ended September 30, 2024. The filing pertains to their f
• Centessa Pharmaceuticals Files 8-K — 8-K · Jan 8, 2025 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on January 8, 2025, reporting a current event. The filing details the company's incorporation in England and Wales and
• Centessa Pharmaceuticals Enters/Terminates Agreements, Incurs Obligation — 8-K · Dec 30, 2024 Risk: medium
  Centessa Pharmaceuticals plc entered into a material definitive agreement and terminated another on December 30, 2024. The company also incurred a direct financ
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• SC 13G/A Filing — SC 13G/A · Nov 14, 2024
• Centessa Pharmaceuticals Q3 2024 10-Q Filing — 10-Q · Nov 12, 2024 Risk: medium
  Centessa Pharmaceuticals plc filed its 10-Q for the period ending September 30, 2024. The filing details financial performance and operational updates for the t
• Centessa Pharmaceuticals Files 10-Q/A for Q2 2024 — 10-Q/A · Oct 18, 2024 Risk: low
  Centessa Pharmaceuticals plc filed an amendment (10-Q/A) on October 18, 2024, for the quarterly period ended June 30, 2024. The filing pertains to their operati
• Centessa Pharmaceuticals Enters Material Definitive Agreement — 8-K · Sep 13, 2024 Risk: medium
  On September 12, 2024, Centessa Pharmaceuticals plc entered into a material definitive agreement. The company also reported other events and filed financial sta
• Centessa Pharmaceuticals Files 8-K with Corporate Updates — 8-K · Sep 10, 2024 Risk: low
  Centessa Pharmaceuticals plc announced on September 10, 2024, that it is filing a Form 8-K. The filing provides updated information regarding the company's corp
• Centessa Pharmaceuticals Files Q2 2024 10-Q — 10-Q · Aug 13, 2024 Risk: low
  Centessa Pharmaceuticals plc filed its 10-Q for the period ending June 30, 2024, reporting on its financial performance. The company's fiscal year ends on Decem
• Centessa Pharmaceuticals Files 8-K on Shareholder Votes — 8-K · Jun 25, 2024 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on June 25, 2024, to report on matters submitted to a vote of its security holders. The filing does not contain specif
• Centessa Pharmaceuticals CMO Departs; Severance Package Detailed — 8-K · Jun 10, 2024 Risk: medium
  Centessa Pharmaceuticals plc announced on June 5, 2024, the departure of its Chief Medical Officer, Dr. Andrew Allen, effective immediately. The company also di
• Centessa Pharmaceuticals Files Definitive Additional Materials — DEFA14A · May 21, 2024 Risk: low
  Centessa Pharmaceuticals plc filed definitive additional materials on May 21, 2024, related to its proxy statement. The filing concerns the company's operations
• Centessa Pharmaceuticals plc Files 10-Q for Period Ending March 31, 2024 — 10-Q · May 13, 2024 Risk: medium
  Centessa Pharmaceuticals plc (CNTA) filed a Quarterly Report (10-Q) with the SEC on May 13, 2024. Centessa Pharmaceuticals plc filed a 10-Q report for the perio
• Centessa Pharmaceuticals plc Announces 2024 Annual General Meeting — DEF 14A · May 9, 2024 Risk: low
  Centessa Pharmaceuticals plc (CNTA) filed a Proxy Statement (DEF 14A) with the SEC on May 9, 2024. The 2024 Annual General Meeting (AGM) of Centessa Pharmaceuti
• Centessa Pharmaceuticals Enters Material Agreement — 8-K · Apr 24, 2024 Risk: medium
  Centessa Pharmaceuticals plc announced on April 23, 2024, that it has entered into a material definitive agreement. The company also reported its results of ope
• Centessa Pharmaceuticals Files 8-K — 8-K · Apr 22, 2024 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on April 22, 2024, reporting on other events and financial statements. The filing does not contain specific financial
• Centessa Pharmaceuticals plc Files 2023 Annual Report on Form 10-K — 10-K · Mar 28, 2024 Risk:
  Centessa Pharmaceuticals plc (CNTA) filed a Annual Report (10-K) with the SEC on March 28, 2024. Centessa Pharmaceuticals plc filed its 10-K report for the fisc
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• SC 13G/A Filing — SC 13G/A · Feb 14, 2024
• Centessa Confirms Ordinary Shares Listed on Nasdaq Under CNTA — 8-K · Feb 9, 2024 Risk: low
  Centessa Pharmaceuticals plc filed an 8-K on February 9, 2024, to update its registered securities. The filing clarifies that its Ordinary shares, with a nomina
• Centessa Pharma Confirms Ordinary Shares Listed on Nasdaq — 8-K · Jan 9, 2024
  Centessa Pharmaceuticals plc filed an 8-K on January 9, 2024, to update its registration of securities. The company clarified that its Ordinary shares, with a n

Risk Profile

Risk Assessment: Of CNTA's 30 recent filings, 2 were flagged as high-risk, 9 as medium-risk, and 19 as low-risk. The overall risk profile suggests relatively low risk with generally favorable filings.

Financial Highlights

Key financial metrics from Centessa Pharmaceuticals PLC's most recent 10-Q filing (Nov 5, 2025):

• Revenue: $15.00M
• Net Income: -$131.37M
• EPS: N/A
• Debt-to-Equity: 0.49
• Cash Position: $50.81M
• Operating Margin: N/A
• Total Assets: $448.30M
• Total Debt: $109.82M

Key Executives

• Dr. Andrew Allen

Industry Context

Centessa Pharmaceuticals operates in the highly competitive and capital-intensive biopharmaceutical industry, focusing on novel drug discovery. The sector is characterized by long development cycles, high R&D costs, and significant regulatory hurdles. Success hinges on innovation, clinical trial outcomes, and the ability to secure substantial funding for pipeline advancement.

Top Tags

regulatory-filing (6) · corporate-governance (6) · material-agreement (5) · filing (4) · quarterly-report (4) · shareholder-meeting (3) · 8-K (3) · proxy-statement (3) · 10-Q (3) · Centessa Pharmaceuticals (3)

Key Numbers

• Cash and cash equivalents: $50.81M — Decreased from $383.22M at Dec 31, 2024, indicating rapid cash burn.
• Net loss for nine months: $131.37M — Increased from $124.43M in the prior year, showing continued unprofitability.
• Research and development expenses for Q3: $41.56M — Increased from $33.90M in Q3 2024, reflecting higher investment in pipeline.
• License and other revenue for nine months: $15.00M — First reported revenue, but no revenue in current quarter or prior year Q3.
• Ordinary shares outstanding: 134,447,836 — As of October 31, 2025, indicating potential for further dilution.
• Net Loss (Q2 2025): $50.343M — Increased from $43.816M in Q2 2024
• Net Loss (YTD Q2 2025): $76.478M — Improved from $81.862M in YTD Q2 2024 due to revenue
• Research and Development Expenses (Q2 2025): $42.741M — Increased from $32.815M in Q2 2024
• Cash and Cash Equivalents (June 30, 2025): $44.242M — Significant decrease from $383.221M at Dec 31, 2024
• Accumulated Deficit (June 30, 2025): $1,065.180M — Increased from $988.702M at Dec 31, 2024
• License and Other Revenue (YTD Q2 2025): $15.000M — New revenue stream compared to $0 in YTD Q2 2024
• Ordinary Shares Outstanding (August 1, 2025): 134,073,436 — Indicates potential for future dilution
• Reporting Period End Date: 2025-03-31 — Indicates the end of the financial quarter being reported.
• Reporting Period Start Date: 2025-01-01 — Indicates the start of the financial quarter being reported.
• Prior Period End Date: 2024-12-31 — Provides a comparison point to the previous fiscal year-end.

Frequently Asked Questions